logo

For the Inventor, By the Inventor

Osaka, Japan

Tatsuya Komagata

This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignee: Ono Pharmaceutical Co., Ltd.. Active years: 2017-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tatsuya Komagata. Retrieved from https://idiyas.com/inventor/tatsuya-komagata

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 50.0

 

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 25(Granted Patents)


Company Filing History:

goldMedal4 out of 575 
 
Ono Pharmaceutical Co., Ltd.
 patents

Years Active: 2017-2019

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents
1. 10214540 - Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes (2019-02-26),
2. 9975904 - Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes (2018-05-22),
3. 9643951 - Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof (2017-05-09),
4. 9630976 - Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes (2017-04-25),

Title: Tatsuya Komagata: Innovator in Somatostatin Receptor Agonists

Introduction

Tatsuya Komagata is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medical research, particularly in the development of compounds that target somatostatin receptors. With a total of 4 patents to his name, Komagata's work is paving the way for new therapeutic options.

Latest Patents

One of Komagata's latest patents focuses on a compound that exhibits agonistic activity on somatostatin receptors. This compound is designed to be orally available and low in toxicity, making it a promising candidate for medical applications. Specifically, it is useful for the prevention and treatment of somatostatin-related diseases such as acromegaly and gastrointestinal obstruction. The compound is characterized as a non-peptidic low-molecular entity with strong agonist activity on somatostatin receptor subtype 2.

Career Highlights

Tatsuya Komagata is currently employed at Ono Pharmaceutical Co., Ltd., where he continues to innovate in the field of pharmaceuticals. His research has the potential to significantly impact the treatment of various medical conditions related to somatostatin.

Collaborations

Throughout his career, Komagata has collaborated with notable colleagues, including Akiharu Ishida and Takeshi Matsushita. These collaborations have further enhanced the scope and impact of his research.

Conclusion

Tatsuya Komagata is a key figure in the development of somatostatin receptor agonists, with a focus on creating effective and safe medical treatments. His contributions to the field are invaluable and continue to inspire future innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…